EC
SYRE icon

EcoR1 Capital’s Spyre Therapeutics SYRE Stock Holding History

EcoR1 Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-887,076
Closed -$19.1M – 65
2023
Q4 		$19.1M Buy
887,076
+687,080
+344% +$9.47M 0.5% 32
2023
Q3 		$2.45M Sell
199,996
-4
-0% -$53 0.08% 44
2023
Q2 		$2.25M Buy
+200,000
New +$948K 0.06% 45

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

EcoR1 Capital's SYRE Position: Q1 2024 in Review

EcoR1 Capital sold out of Spyre Therapeutics (SYRE) in Q1 2024, closing a stake of 887,076 shares — an estimated $19.1M sold.

EcoR1 Capital first reported a position in SYRE in Q2 2023 and held it in 3 quarters. The position peaked at $19.1M in Q4 2023. 103 funds tracked by Wall St. Rank hold SYRE as of Q1 2024.

  • EcoR1 Capital reported no remaining Spyre Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EcoR1 Capital sold 887,076 Spyre Therapeutics shares in Q1 2024, an estimated $19.1M.
  • EcoR1 Capital first reported a position in Spyre Therapeutics in Q2 2023 and held it in 3 quarters.
  • EcoR1 Capital's Spyre Therapeutics position peaked at $19.1M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2024.

Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.